111 related articles for article (PubMed ID: 38305286)
21. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
22. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
Wang Y; Zhang G; Wang R
Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
Zhang JT; Lin YC; Xiao BF; Yu BT
Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
[TBL] [Abstract][Full Text] [Related]
24. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
25. Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.
Yang X; Zheng Y; Han Z; Zhang X
BMC Cancer; 2021 Jun; 21(1):752. PubMed ID: 34187403
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia.
Zhang T; Wang J; Zhou X; Liang R; Bai Q; Yang L; Gu H; Gao G; Dong B; Zhu H; Chen X
J Cell Biochem; 2014 Nov; 115(11):1918-27. PubMed ID: 24905442
[TBL] [Abstract][Full Text] [Related]
28. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
29. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
Chen A; Ding S; Shen X; Lin X
Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321
[TBL] [Abstract][Full Text] [Related]
30. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
Wang H; Wang X; Xu L; Cao H; Zhang J
Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
[TBL] [Abstract][Full Text] [Related]
31. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.
Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H
Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503
[TBL] [Abstract][Full Text] [Related]
32. Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach.
Aluksanasuwan S; Somsuan K; Ngoenkam J; Chutipongtanate S; Pongcharoen S
Cancer Biomark; 2024; 39(3):155-170. PubMed ID: 37694354
[TBL] [Abstract][Full Text] [Related]
33. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
34. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
[TBL] [Abstract][Full Text] [Related]
35. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
36. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.
Hu HB; Yang XP; Zhou PX; Yang XA; Yin B
Genes Genomics; 2020 Feb; 42(2):179-188. PubMed ID: 31768767
[TBL] [Abstract][Full Text] [Related]
37. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
38. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
[TBL] [Abstract][Full Text] [Related]
39. High expression of prolyl 4-hydroxylase subunit alpha-2 in lung adenocarcinoma indicates poor prognosis.
Lu XH; Sang D; Zhang YR; Yuan Q
Clinics (Sao Paulo); 2022; 77():100123. PubMed ID: 36403427
[TBL] [Abstract][Full Text] [Related]
40. PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18.
Tang J; Meng Q; Shi R; Xu Y
Mol Med Rep; 2020 Oct; 22(4):3161-3172. PubMed ID: 32945431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
